Inscrição na biblioteca: Guest
Journal of Environmental Pathology, Toxicology and Oncology

Publicou 4 edições por ano

ISSN Imprimir: 0731-8898

ISSN On-line: 2162-6537

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.4 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.8 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.5 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00049 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.59 SJR: 0.429 SNIP: 0.507 CiteScore™:: 3.9 H-Index: 49

Indexed in

Melatonin Improves Behavioral and Biochemical Outcomes in a Rotenone-Induced Rat Model of Parkinson's Disease

Volume 37, Edição 2, 2018, pp. 139-150
DOI: 10.1615/JEnvironPatholToxicolOncol.2018025666
Get accessGet access

RESUMO

Parkinson's disease (PD) is the second most common neurodegenerative disease followed only by Alzheimer's disease and affects millions of people worldwide. Despite the plethora of preclinical and clinical studies, there is currently a paucity of therapeutic agents for PD that can promote neuroprotection. In addition, the therapeutic agents currently available only help with improvement of PD symptoms. Therefore, it is imperative to find new therapeutic avenues for PD patients to minimize the economic and social burden on the concerned families. Rotenone is a frequently used neurotoxin in developing a PD model to aid in understanding the mechanisms of neuronal death. In addition, several studies have investigated the effects of melatonin, a neurohormone that is neuroprotective in various neurological diseases due to its anti-apoptotic, anti-inflammatory, and anti-oxidative properties. Our study investigated the role of melatonin-induced tyrosine hydroxylase (TH) and sensory motor function in a rotenone rat model to determine whether melatonin had any positive effects. Our results revealed that melatonin improves motor function by upregulation of TH in striatum of the brain. In addition, melatonin inhibits the striatal degeneration as shown by histopathological analysis. Therefore, results from the current study provide evidence for melatonin as a promising candidate for effective future therapeutic strategies for PD.

CITADO POR
  1. Zuo , Prather , Stetskiv , Garrison , Meade , Peace , Zhou , Inflammaging and Oxidative Stress in Human Diseases: From Molecular Mechanisms to Novel Treatments, International Journal of Molecular Sciences, 20, 18, 2019. Crossref

  2. Pernold Karin, Iannello F., Low B. E., Rigamonti M., Rosati G., Scavizzi F., Wang J., Raspa M., Wiles M. V., Ulfhake B., Mintz Eric M., Towards large scale automated cage monitoring – Diurnal rhythm and impact of interventions on in-cage activity of C57BL/6J mice recorded 24/7 with a non-disrupting capacitive-based technique, PLOS ONE, 14, 2, 2019. Crossref

  3. Daneshvar Kakhaki Reza, Ostadmohammadi Vahidreza, Kouchaki Ebrahim, Aghadavod Esmat, Bahmani Fereshteh, Tamtaji Omid Reza, J.Reiter Russel, Mansournia Mohammad Ali, Asemi Zatollah, Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial, Clinical Neurology and Neurosurgery, 195, 2020. Crossref

  4. Salman Mohd., Tabassum Heena, Parvez Suhel, Tannic Acid Provides Neuroprotective Effects Against Traumatic Brain Injury Through the PGC-1α/Nrf2/HO-1 Pathway, Molecular Neurobiology, 57, 6, 2020. Crossref

  5. Salman Mohd., Kaushik Pooja, Tabassum Heena, Parvez Suhel, Melatonin Provides Neuroprotection Following Traumatic Brain Injury-Promoted Mitochondrial Perturbation in Wistar Rat, Cellular and Molecular Neurobiology, 41, 4, 2021. Crossref

  6. Percário Sandro, da Silva Barbosa Aline, Varela Everton Luiz Pompeu, Gomes Antônio Rafael Quadros, Ferreira Michelli Erica Souza, de Nazaré Araújo Moreira Thayana, Dolabela Maria Fani, Morales Patricia, Oxidative Stress in Parkinson’s Disease: Potential Benefits of Antioxidant Supplementation, Oxidative Medicine and Cellular Longevity, 2020, 2020. Crossref

  7. Ferlazzo Nadia, Andolina Giulia, Cannata Attilio, Costanzo Maria Giovanna, Rizzo Valentina, Currò Monica, Ientile Riccardo, Caccamo Daniela, Is Melatonin the Cornucopia of the 21st Century?, Antioxidants, 9, 11, 2020. Crossref

  8. Juárez-Flores Diana Luz, Ezquerra Mario, Gonzàlez-Casacuberta ïngrid, Ormazabal Aida, Morén Constanza, Tolosa Eduardo, Fucho Raquel, Guitart-Mampel Mariona, Casado Mercedes, Valldeoriola Francesc, de la Torre-Lara Joan, Muñoz Esteban, Tobías Ester, Compta Yaroslau, García-García Francesc Josep, García-Ruiz Carmen, Fernandez-Checa Jose Carlos, Martí Maria José, Grau Josep Maria, Cardellach Francesc, Artuch Rafael, Fernández-Santiago Rubén, Garrabou Glòria, Disrupted Mitochondrial and Metabolic Plasticity Underlie Comorbidity between Age-Related and Degenerative Disorders as Parkinson Disease and Type 2 Diabetes Mellitus, Antioxidants, 9, 11, 2020. Crossref

  9. Salman Mohd., Tabassum Heena, Parvez Suhel, Nrf2/HO-1 mediates neuroprotective effects of pramipexole by attenuating oxidative damage and mitochondrial perturbation after traumatic brain injury, Disease Models & Mechanisms, 2020. Crossref

  10. Bjørklund Geir, Dadar Maryam, Anderson George, Chirumbolo Salvatore, Maes Michael, Preventive treatments to slow substantia nigra damage and Parkinson’s disease progression: A critical perspective review, Pharmacological Research, 161, 2020. Crossref

  11. Pérez-Lloret Santiago, Cardinali Daniel P., Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson’s Disease, Frontiers in Pharmacology, 12, 2021. Crossref

  12. Zhou Qiuping, Lin Lanfen, Li Haiyan, Wang Huifang, Jiang Shuqi, Huang Peixian, Lin Qiongyu, Chen Xuan, Deng Yiyu, Melatonin Reduces Neuroinflammation and Improves Axonal Hypomyelination by Modulating M1/M2 Microglia Polarization via JAK2-STAT3-Telomerase Pathway in Postnatal Rats Exposed to Lipopolysaccharide, Molecular Neurobiology, 58, 12, 2021. Crossref

  13. Ortíz de Zárate Ana, Pérez-Torralba Marta, Bonet Isidro Iñigo, López Concepción, Claramunt Rosa M., Martínez-Casanova Diana, Sánchez-Vera Isabel, Jiménez-González Jesús, Lavandera José Luis, 1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents, Antioxidants, 10, 10, 2021. Crossref

  14. Salman Mohd, Tabassum Heena, Parvez Suhel, Piperine mitigates behavioral impairments and provides neuroprotection against 3-nitropropinoic acid-induced Huntington disease-like symptoms, Nutritional Neuroscience, 25, 1, 2022. Crossref

  15. Bayraktar U. Arda, Arıhan Okan, Atalay Özbeyen, Gök Müslüm, Çiçek Çiğdem, Bodur Ebru, Tuncer Meltem, Melatonin is effective in attenuating cisplatin‐induced neurotoxicity, Journal of Biochemical and Molecular Toxicology, 36, 7, 2022. Crossref

Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain